Ion channel
OwnerNicola Brice, Mark Carlton +3inventors
InventorsNicola Brice, Mark Carlton, John Dixon, Isabelle Malinge, Dirk Zahn
Life of this patent
Estimating the term…
Abstract
Provided are Kv9.2 polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof. Nucleic acids capable of encoding Kv9.2 polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID No. 1, SEQ ID No.2 or SEQ ID NO: 4. Methods of identifying Kv9.2 agonists and antagonists are also provided.
Claims29
A method of identifying a compound capable of binding to Kv9.2 polypeptide, the method comprising:
- (a) contacting a Kv9.2 polypeptide with a candidate compound;
- and
- (b) determining whether the candidate compound binds to the Kv9.2 polypeptide;
- wherein the compound is suitable for treating or alleviating anxiety in an individual, wherein the anxiety is associated with activity of Kv9.2.
A method of identifying a compound for treating or alleviating anxiety comprising:
- (a) administering a candidate compound capable of binding to Kv9.2 polypeptide to an animal;
- and
- (b) determining whether the animal exhibits a change in anxiety;
- thereby identifying a compound for treating or alleviating anxiety.
A method of identifying an agonist of Kv9.2 polypeptide, the method comprising:
- (a) administering a candidate compound capable of binding to Kv9.2 polypeptide to an animal;
- and
- (b) determining whether the animal exhibits an increase in anxiety;
- thereby identifying an agonist of Kv9.2 polypeptide.
A method of identifying an antagonist of Kv9.2 polypeptide the method comprising:
- (a) administering a candidate compound capable of binding to Kv9.2 polypeptide to an animal;
- and
- (b) determining whether the animal exhibits a decrease in anxiety;
- thereby identifying an antagonist of Kv9.2 polypeptide.
A method of treating an individual suffering from anxiety, wherein the anxiety is associated with Kv9.2 activity, the method comprising administering an antagonist of Kv9.2 to the individual.
A method of diagnosing susceptibility to anxiety in an individual, wherein the anxiety is associated with Kv9.2 activity, the method comprising detecting a change in expression pattern or level of Kv9.2 in a cell or tissue of the individual.
A method of diagnosing susceptibility to anxiety in an individual, wherein the anxiety is associated with Kv9.2 activity, the method comprising detecting a polymorphism in a Kv9.2 polynucleotide in a cell or tissue of the individual.
A transgenic non-human mammal comprising a disruption in the endogenous Kv9.2 gene, wherein the disruption results in a change in anxiety in the mammal.
Dependencies are inferred from the claim text.